vs

Side-by-side financial comparison of BIO-RAD LABORATORIES, INC. (BIO) and Quanterix Corp (QTRX). Click either name above to swap in a different company.

BIO-RAD LABORATORIES, INC. is the larger business by last-quarter revenue ($693.2M vs $43.9M, roughly 15.8× Quanterix Corp). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs -52.7%, a 156.6% gap on every dollar of revenue. On growth, Quanterix Corp posted the faster year-over-year revenue change (24.7% vs 3.9%). BIO-RAD LABORATORIES, INC. produced more free cash flow last quarter ($119.1M vs $-16.5M). Over the past eight quarters, Quanterix Corp's revenue compounded faster (16.9% CAGR vs 6.5%).

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.

Quanterix Corp is a life sciences firm that develops, manufactures, and commercializes ultra-sensitive single-molecule detection diagnostic platforms, reagents, and testing services. Its solutions empower biological research, drug development, and clinical diagnostics across oncology, neurodegenerative disorders, infectious diseases, and other therapeutic areas, serving research institutions, biopharmaceutical companies, and clinical laboratories globally.

BIO vs QTRX — Head-to-Head

Bigger by revenue
BIO
BIO
15.8× larger
BIO
$693.2M
$43.9M
QTRX
Growing faster (revenue YoY)
QTRX
QTRX
+20.9% gap
QTRX
24.7%
3.9%
BIO
Higher net margin
BIO
BIO
156.6% more per $
BIO
103.9%
-52.7%
QTRX
More free cash flow
BIO
BIO
$135.6M more FCF
BIO
$119.1M
$-16.5M
QTRX
Faster 2-yr revenue CAGR
QTRX
QTRX
Annualised
QTRX
16.9%
6.5%
BIO

Income Statement — Q4 2025 vs Q4 2025

Metric
BIO
BIO
QTRX
QTRX
Revenue
$693.2M
$43.9M
Net Profit
$720.0M
$-23.1M
Gross Margin
49.8%
45.7%
Operating Margin
-17.2%
-56.4%
Net Margin
103.9%
-52.7%
Revenue YoY
3.9%
24.7%
Net Profit YoY
200.6%
-98.8%
EPS (diluted)
$26.59
$-0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIO
BIO
QTRX
QTRX
Q4 25
$693.2M
$43.9M
Q3 25
$653.0M
$40.2M
Q2 25
$651.6M
$24.5M
Q1 25
$585.4M
$30.3M
Q4 24
$667.5M
$35.2M
Q3 24
$649.7M
$35.8M
Q2 24
$638.5M
$34.4M
Q1 24
$610.8M
$32.1M
Net Profit
BIO
BIO
QTRX
QTRX
Q4 25
$720.0M
$-23.1M
Q3 25
$-341.9M
$-33.5M
Q2 25
$317.8M
$-30.0M
Q1 25
$64.0M
$-20.5M
Q4 24
$-715.8M
$-11.6M
Q3 24
$653.2M
$-8.4M
Q2 24
$-2.2B
$-7.4M
Q1 24
$383.9M
$-11.2M
Gross Margin
BIO
BIO
QTRX
QTRX
Q4 25
49.8%
45.7%
Q3 25
52.6%
42.8%
Q2 25
53.0%
46.2%
Q1 25
52.3%
54.1%
Q4 24
51.2%
63.0%
Q3 24
54.8%
56.3%
Q2 24
55.6%
64.7%
Q1 24
53.4%
57.8%
Operating Margin
BIO
BIO
QTRX
QTRX
Q4 25
-17.2%
-56.4%
Q3 25
10.0%
-92.8%
Q2 25
11.8%
-151.6%
Q1 25
4.0%
-86.9%
Q4 24
8.7%
-42.0%
Q3 24
9.9%
-32.8%
Q2 24
15.9%
-31.8%
Q1 24
7.3%
-47.3%
Net Margin
BIO
BIO
QTRX
QTRX
Q4 25
103.9%
-52.7%
Q3 25
-52.4%
-83.3%
Q2 25
48.8%
-122.6%
Q1 25
10.9%
-67.6%
Q4 24
-107.2%
-33.1%
Q3 24
100.5%
-23.3%
Q2 24
-339.2%
-21.5%
Q1 24
62.9%
-34.8%
EPS (diluted)
BIO
BIO
QTRX
QTRX
Q4 25
$26.59
$-0.48
Q3 25
$-12.70
$-0.73
Q2 25
$11.67
$-0.77
Q1 25
$2.29
$-0.53
Q4 24
$-25.89
$-0.30
Q3 24
$23.34
$-0.22
Q2 24
$-76.26
$-0.19
Q1 24
$13.45
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIO
BIO
QTRX
QTRX
Cash + ST InvestmentsLiquidity on hand
$1.5B
$29.8M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$7.5B
$295.7M
Total Assets
$10.6B
$418.8M
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIO
BIO
QTRX
QTRX
Q4 25
$1.5B
$29.8M
Q3 25
$1.4B
$38.3M
Q2 25
$1.4B
$132.9M
Q1 25
$1.7B
$76.5M
Q4 24
$1.7B
$56.7M
Q3 24
$1.6B
$29.3M
Q2 24
$1.6B
$47.0M
Q1 24
$1.6B
$45.3M
Total Debt
BIO
BIO
QTRX
QTRX
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
Q1 25
Q4 24
$1.2B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BIO
BIO
QTRX
QTRX
Q4 25
$7.5B
$295.7M
Q3 25
$6.7B
$314.5M
Q2 25
$7.1B
$292.5M
Q1 25
$6.7B
$316.4M
Q4 24
$6.6B
$330.0M
Q3 24
$7.5B
$338.9M
Q2 24
$6.8B
$340.8M
Q1 24
$9.1B
$343.4M
Total Assets
BIO
BIO
QTRX
QTRX
Q4 25
$10.6B
$418.8M
Q3 25
$9.7B
$444.1M
Q2 25
$10.2B
$375.6M
Q1 25
$9.5B
$396.5M
Q4 24
$9.4B
$406.5M
Q3 24
$10.6B
$411.0M
Q2 24
$9.7B
$415.9M
Q1 24
$12.6B
$414.2M
Debt / Equity
BIO
BIO
QTRX
QTRX
Q4 25
0.16×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.18×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIO
BIO
QTRX
QTRX
Operating Cash FlowLast quarter
$164.9M
$-16.4M
Free Cash FlowOCF − Capex
$119.1M
$-16.5M
FCF MarginFCF / Revenue
17.2%
-37.7%
Capex IntensityCapex / Revenue
6.6%
0.2%
Cash ConversionOCF / Net Profit
0.23×
TTM Free Cash FlowTrailing 4 quarters
$374.6M
$-80.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIO
BIO
QTRX
QTRX
Q4 25
$164.9M
$-16.4M
Q3 25
$120.9M
$-41.2M
Q2 25
$116.5M
$-5.7M
Q1 25
$129.9M
$-13.9M
Q4 24
$124.2M
$-4.3M
Q3 24
$163.6M
$-5.7M
Q2 24
$97.6M
$-5.0M
Q1 24
$69.8M
$-20.2M
Free Cash Flow
BIO
BIO
QTRX
QTRX
Q4 25
$119.1M
$-16.5M
Q3 25
$89.2M
$-41.9M
Q2 25
$70.8M
$-6.4M
Q1 25
$95.5M
$-15.1M
Q4 24
$81.2M
$-4.7M
Q3 24
$123.4M
$-6.6M
Q2 24
$55.4M
$-6.5M
Q1 24
$29.6M
$-20.7M
FCF Margin
BIO
BIO
QTRX
QTRX
Q4 25
17.2%
-37.7%
Q3 25
13.7%
-104.2%
Q2 25
10.9%
-26.3%
Q1 25
16.3%
-49.9%
Q4 24
12.2%
-13.4%
Q3 24
19.0%
-18.4%
Q2 24
8.7%
-19.1%
Q1 24
4.8%
-64.5%
Capex Intensity
BIO
BIO
QTRX
QTRX
Q4 25
6.6%
0.2%
Q3 25
4.9%
1.7%
Q2 25
7.0%
3.2%
Q1 25
5.9%
4.1%
Q4 24
6.4%
1.2%
Q3 24
6.2%
2.4%
Q2 24
6.6%
4.7%
Q1 24
6.6%
1.6%
Cash Conversion
BIO
BIO
QTRX
QTRX
Q4 25
0.23×
Q3 25
Q2 25
0.37×
Q1 25
2.03×
Q4 24
Q3 24
0.25×
Q2 24
Q1 24
0.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIO
BIO

Clinical Diagnostics$425.3M61%
Life Science$267.9M39%

QTRX
QTRX

Products$29.2M67%
Consumable And Other Products$12.7M29%
Service Type Warranties$1.7M4%

Related Comparisons